177 related articles for article (PubMed ID: 36366525)
1. Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection.
Chien SC; Lin YJ; Lee CT; Chiu YC; Chou TC; Chiu HC; Tsai HW; Su CM; Yang TH; Chiang HC; Tsai WC; Yang KC; Cheng PN
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366525
[TBL] [Abstract][Full Text] [Related]
2. Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis.
Lamm R; Altshuler PJ; Patel K; Shaheen O; Amante AP; Civan J; Maley W; Frank A; Ramirez C; Glorioso J; Shah A; Dang H; Bodzin AS
Transpl Int; 2022; 35():10175. PubMed ID: 35865863
[TBL] [Abstract][Full Text] [Related]
3. Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC.
Yang T; Hu LY; Li ZL; Liu K; Wu H; Xing H; Lau WY; Pawlik TM; Zeng YY; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Li C; Wang MD; Wu MC; Shen F
J Gastrointest Surg; 2020 Feb; 24(2):320-329. PubMed ID: 30617773
[TBL] [Abstract][Full Text] [Related]
4. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma.
Sadler EM; Mehta N; Bhat M; Ghanekar A; Greig PD; Grant DR; Yao F; Sapisochin G
Transplantation; 2018 Apr; 102(4):640-647. PubMed ID: 29319620
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
Reddy SK; Steel JL; Chen HW; DeMateo DJ; Cardinal J; Behari J; Humar A; Marsh JW; Geller DA; Tsung A
Hepatology; 2012 Jun; 55(6):1809-19. PubMed ID: 22183968
[TBL] [Abstract][Full Text] [Related]
6. Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma.
Hester CA; Rich NE; Singal AG; Yopp AC
J Natl Compr Canc Netw; 2019 Apr; 17(4):322-329. PubMed ID: 30959469
[TBL] [Abstract][Full Text] [Related]
7. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.
Pal Chaudhary S; Reyes S; Chase ML; Govindan A; Zhao L; Luther J; Bhan I; Bethea E; Franses JW; Paige Walsh E; Anne Dageford L; Kimura S; Elias N; Yeh H; Markman J; Bozorgzadeh A; Tanabe K; Ferrone C; Zhu AX; Andersson K; Thiim M; Antonio Catalano O; Kambadakone A; Vagefi PA; Qadan M; Pratt D; Hashemi N; Corey KE; Misdraji J; Goyal L; Clark JW
Oncologist; 2023 Apr; 28(4):341-350. PubMed ID: 36763374
[TBL] [Abstract][Full Text] [Related]
8. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
10. Novel Models Predict Postsurgical Recurrence and Overall Survival for Patients with Hepatitis B Virus-Related Solitary Hepatocellular Carcinoma ≤10 cm and Without Portal Venous Tumor Thrombus.
Wang XH; Liao B; Hu WJ; Tu CX; Xiang CL; Hao SH; Mao XH; Qiu XM; Yang XJ; Yue X; Kuang M; Peng BG; Li SQ
Oncologist; 2020 Oct; 25(10):e1552-e1561. PubMed ID: 32663354
[TBL] [Abstract][Full Text] [Related]
11. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
[TBL] [Abstract][Full Text] [Related]
12. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load.
Sohn W; Paik YH; Cho JY; Ahn JM; Choi GS; Kim JM; Kwon CH; Joh JW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
J Viral Hepat; 2015 Jun; 22(6):539-50. PubMed ID: 25377516
[TBL] [Abstract][Full Text] [Related]
13. Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis.
Billeter AT; Müller PC; Albrecht T; Roessler S; Löffler M; Lemekhova A; Mehrabi A; Müller-Stich BP; Hoffmann K
J Gastrointest Surg; 2021 May; 25(5):1193-1202. PubMed ID: 32378092
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Holzner ML; Florman S; Schwartz ME; Tabrizian P
HPB (Oxford); 2022 Apr; 24(4):470-477. PubMed ID: 34544629
[TBL] [Abstract][Full Text] [Related]
15. Diabetes Mellitus and/or Nonalcoholic Steatohepatitis-related Hepatocellular Carcinoma Showed Favorable Surgical Outcomes After Hepatectomy.
Liang J; Ariizumi SI; Nakano M; Yamamoto M
Anticancer Res; 2019 Oct; 39(10):5639-5643. PubMed ID: 31570461
[TBL] [Abstract][Full Text] [Related]
16. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma.
Hernandez-Alejandro R; Croome KP; Drage M; Sela N; Parfitt J; Chandok N; Marotta P; Dale C; Wall W; Quan D
World J Gastroenterol; 2012 Aug; 18(31):4145-9. PubMed ID: 22919246
[TBL] [Abstract][Full Text] [Related]
17. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis.
Yang T; Lu JH; Lau WY; Zhang TY; Zhang H; Shen YN; Alshebeeb K; Wu MC; Schwartz M; Shen F
J Hepatol; 2016 Mar; 64(3):583-93. PubMed ID: 26596543
[TBL] [Abstract][Full Text] [Related]
18. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma.
Yang SY; Wang CC; Chen KD; Liu YW; Lin CC; Chuang CH; Tsai YC; Yao CC; Yen YH; Hsiao CC; Hu TH; Tsai MC
BMC Cancer; 2021 Jan; 21(1):70. PubMed ID: 33446127
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma.
Yoon JS; Lee HY; Chung SW; Kim SW; Chang Y; Lee YB; Cho EJ; Lee JH; Yu SJ; Kim H; Yoon JH; Kim YJ
J Gastroenterol Hepatol; 2020 Nov; 35(11):1960-1968. PubMed ID: 32128882
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
[No Abstract] [Full Text] [Related]
[Next] [New Search]
